Our results demonstrated significantly higher levels of CD49d expression in CD8+ compared to CD4+ T-lymphocytes at baseline both in RRMS patients and HD; this significant difference was not seen after 12 and 24 months of natalizumab treatment in RRMS patients. Here, CD4 is linked to Huntington disease.